Aidigong Maternal & Child Health Ltd

Aidigong Maternal & Child Health Ltd has a debt-to-equity ratio of 1.15, indicating a moderate level of leverage. The company's current ratio of 1.16 suggests it has sufficient short-term assets to cover its short-term liabilities, though the margin is narrow. The negative net cash position after subtracting total debt raises concerns about liquidity. The company's profitability is weak, with a return on equity of -24.05% and a return on assets of -9.05%. These figures are significantly below the industry median for healthcare facilities and services, which typically show positive returns. The operating loss of HKD 110.3 million and net loss of HKD 177.4 million further highlight the company's financial challenges. Aidigong's revenue is distributed across three segments: Postpartum Care, Health Industry, and Other. The Postpartum Care segment is the primary revenue driver, but the company's financial snapshot does not provide specific revenue figures for each segment. The geographic exposure is not disclosed in the provided data, but the company is based in Hong Kong and likely serves the broader Asia-Pacific region. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The operating cash flow of HKD 82.7 million is positive, but the free cash flow is negative at HKD -34.1 million, indicating that the company is not generating enough cash to fund its operations and capital expenditures. The capital expenditure of HKD -36.4 million suggests ongoing investment in infrastructure or expansion. The risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after total debt is a red flag for liquidity. The company has not disclosed any recent dilution events, and the dilution risk is currently low. However, the negative net income and operating income suggest potential financial instability. Recent events include the latest financial filing, which shows a revenue of HKD 554.58 million. There are no recent transcripts or filings indicating significant changes in the company's operations or strategy. The analyst estimate for revenue aligns with the reported actual revenue, suggesting no immediate expectations of a turnaround.